Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models

[1]  J. Peiris,et al.  The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice , 2005, Vaccine.

[2]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[3]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[4]  W. Bellini,et al.  Effects of a SARS-associated coronavirus vaccine in monkeys , 2003, The Lancet.

[5]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[6]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[7]  Y. Guan,et al.  Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.

[8]  H. Yoshida,et al.  Production of human monoclonal and polyclonal antibodies in TransChromo animals. , 2002, Cloning and stem cells.

[9]  V. Racaniello Picornaviridae : the viruses and their replication , 2001 .

[10]  P. Padfield,et al.  Generation of an immortal differentiated lung type-II epithelial cell line from the adult H-2KbtsA58 transgenic mouse , 2000, In Vitro Cellular & Developmental Biology - Animal.

[11]  T Nomura,et al.  The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. , 1997, Cancer research.

[12]  T. Kishimoto,et al.  Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. , 1981, Proceedings of the National Academy of Sciences of the United States of America.